[Form 4] IRIDEX CORP Insider Trading Activity

Rhea-AI Filing Summary

Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported purchases of common stock on 09/12/2025. The Form 4 shows two non-derivative acquisitions: 250 shares at $1.37 and 1,200 shares at $1.36, for a total of 1,450 shares acquired. Following the transactions, the filing reports 61,950 shares beneficially owned. The form is signed by an attorney-in-fact on 09/15/2025.

Positive

• Reporting person purchased 1,450 shares (250 at $1.37 and 1,200 at $1.36), indicating an increase in insider ownership.
• Beneficial ownership increased to 61,950 shares following the reported transactions.
• Transactions were disclosed on Form 4, satisfying Section 16 reporting requirements and providing transparency.

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider purchases totaling 1,450 shares reported; ownership rose to 61,950 shares.

The filing documents two open-market purchases by CFO Romeo R. Dizon on 09/12/2025: 250 shares at $1.37 and 1,200 shares at $1.36. These non-derivative acquisitions increased his beneficial ownership to 61,950 shares. Transaction sizes and prices are explicitly reported; there is no additional financial or operational information in the filing to assess material impact on company fundamentals.

Corporate Governance Expert

TL;DR: Form 4 shows routine insider purchases disclosed under Section 16; no governance changes reported.

The document indicates the CFO executed purchases and the Form 4 was timely executed via attorney-in-fact. The filing does not report any change in role, control status, or related-party transactions. This is a standard disclosure of beneficial ownership change with no governance actions disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Dizon Romeo R

(Last) (First) (Middle)

1212 TERRA BELLA AVENUE

(Street)

MOUNTAIN VIEW CA 94043

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/12/2025		P		250	A	$1.37	60,750	D
Common Stock	09/12/2025		P		1,200	A	$1.36	61,950	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Nilo De Castro, Attorney-in-fact for Romeo R. Dizon	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Romeo R. Dizon report on Form 4 for IRIX?

The Form 4 reports two purchases on 09/12/2025: 250 shares at $1.37 and 1,200 shares at $1.36, totaling 1,450 shares acquired.

How many IRIDEX (IRIX) shares does the reporting person own after the transactions?

The filing reports 61,950 shares beneficially owned by the reporting person after the reported transactions.

What is the reporting person's role at IRIDEX according to the Form 4?

The Form 4 identifies the reporting person as an Officer with the title Chief Financial Officer.

When was the Form 4 signed and by whom?

The signature block shows the form was signed by Nilo De Castro, Attorney-in-fact for Romeo R. Dizon on 09/15/2025.

Were any derivative securities or dispositions reported in this Form 4?

No derivative securities or dispositions are reported; Table II is blank and Table I shows only non-derivative acquisitions.